Mobia Medical, Inc. (NASDAQ:MOBI) Receives $20.75 Consensus Price Target from Brokerages

Mobia Medical, Inc. (NASDAQ:MOBI) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $20.75.

MOBI has been the topic of a number of research analyst reports. BTIG Research reiterated a “buy” rating and set a $19.00 target price on shares of Mobia Medical in a research report on Wednesday, August 12th. The Goldman Sachs Group initiated coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Weiss Ratings started coverage on Mobia Medical in a research note on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Finally, Zacks Research upgraded shares of Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd.

Mobia Medical Trading Down 3.1%

MOBI stock opened at $10.61 on Friday. The firm’s 50 day moving average is $12.31. Mobia Medical has a 12-month low of $10.19 and a 12-month high of $15.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The firm has a market cap of $353.21 million and a P/E ratio of -0.53.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The firm had revenue of $13.51 million during the quarter. The business’s revenue was up 102.4% compared to the same quarter last year. Sell-side analysts forecast that Mobia Medical will post -2.76 earnings per share for the current fiscal year.

Insider Transactions at Mobia Medical

In other Mobia Medical news, Director Casey M. Tansey purchased 35,572 shares of the stock in a transaction dated Thursday, August 13th. The shares were acquired at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the transaction, the director directly owned 268,904 shares of the company’s stock, valued at $3,095,085.04. This trade represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Nelson Bunker Curnes purchased 5,000 shares of the stock in a transaction dated Tuesday, June 9th. The stock was acquired at an average price of $12.79 per share, for a total transaction of $63,950.00. Following the completion of the transaction, the chief financial officer directly owned 366,997 shares of the company’s stock, valued at approximately $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 90,000 shares of company stock valued at $1,059,717.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.